CN102188719B - Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma - Google Patents
Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma Download PDFInfo
- Publication number
- CN102188719B CN102188719B CN 201110122249 CN201110122249A CN102188719B CN 102188719 B CN102188719 B CN 102188719B CN 201110122249 CN201110122249 CN 201110122249 CN 201110122249 A CN201110122249 A CN 201110122249A CN 102188719 B CN102188719 B CN 102188719B
- Authority
- CN
- China
- Prior art keywords
- bart3
- antisense oligonucleotide
- mir
- pei
- epstein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a medical application of EB (Epstein-Barr) virus miR-BART3 antisense oligonucleotides, in particular relating to an application of EB virus miR-BART3 antisense oligonucleotides in preparing a medicament for treating nasopharyngeal darcinoma, wherein the sequence of the EB virus miR-BART3 antisense oligonucleotides is ACACCUGGUGACUAGUGGUGCG (SEQ ID NO:1). The EB virus miR-BART3 antisense oligonucleotides can be effectively combined with mature miRNA of the EB virus to block the expression of the miRNA and corresponding regulation action thereof, thus restraining the invasion and metastasis of nasopharyngeal darcinoma cells; and the miRNA has no immunogenifcity, thus being favorable for being further applied in preventing the recurrence and metastasis of the nasopharyngeal darcinoma. The medicament can be used for protecting the antisense oligonucleotides from being degraded by nuclease and prolonging the action time, has higher transfection effciciency than that of commodity liposome, and is favorable for further practical clinical development and application.
Description
Technical field
The invention belongs to and contain the unitary chemical compound of two or more mononucleotides field, particularly relate to chemical compound with the independent phosphate-based or polyphosphoric acid ester group that connects with the saccharide radical of nucleoside base.
Background technology
Nasopharyngeal carcinoma (NPC) is the common head-neck malignant tumor of China's southern area; Be relapse rate and the highest disease of the rate of transform in the tumor of head and neck; The cervical lymph node rate of transform is up to 80%, cures to still have 20～30% patients the recurrence and the transfer of nasopharyngeal carcinoma to occur in back 5 years, and be to cause one of dead principal element clinically; Traditional treatment means such as operation, radiotherapy or chemotherapy etc. are undesirable to recurrence, the transfer effect of preventing and treating nasopharyngeal carcinoma; Comparatively speaking, the applying biological Therapeutic Method is more suitable for the treatment of second stage, and wherein gene therapy has prior clinical meaning to recurrence, the transfer that prevents and treats nasopharyngeal carcinoma.
(Epstein Barr virus EBV) is a kind of gamma herpes viruses to Epstein-Barr virus, and nearly all not differentiation is all relevant with the Epstein-Barr virus latent infection with low differentiation nasopharyngeal carcinoma.Recently the gene that the miRNA that discovers Epstein-Barr virus coding can participate in the Epstein-Barr virus coding and human host's expression of gene EBV-miR-BART2 can with the 3`UTR complementation fully of the gene BALF5 of coding viral dna polymerase.When a large amount of virus replication of cracking infection period, the miR-BART2 expression reduces, and the decomposition of BALF5 gene is weakened, and helps the virus replication circulation.Along with the miR-BART2 selection pressure changes, BALF5 expresses reduction, and the virion that the EBV infection cell discharges constantly reduces, and infects to get into latency (Nucleic Acids Res 37:1035-48,2009); EBV-miR-BHRFI-3 is relevant with the expression of the inductive T cell chemotactic factor of cell IFN CXCL-11/I-TAC; Infer that CXCL-11/I-TAC is the miR-BHRFl-3 action target spot; Epstein-Barr virus can this disturb host's immune surveillance and immune clearance effect (Cancer Res 68:1436-42,2008) as regulative mode; EBV-miR-BART5 can raise the expression of P53 through albumen PUMAHl before the apoptosis that suppresses the host.If from the cell that EBV infects, remove miR-BART5, will promote the effect of PUMA mediated Apoptosis, prompting EBV can suppress the generation of apoptosis; Thereby protect epithelial cell (the J Exp Med 205:2551-60 of its infection; 2008, J Biol Chem 285:33358-70,2010); MiR-BART6-5p can suppress the expression of EBNA2 viral oncogene; And I type that is expressed in of this oncogene and II type latency (immune low reaction) are indispensable in the process that III type latency (the high reaction of immunity) transforms; Show miR-BART6 performance important regulatory role (J Biol Chem 285:33358-70,2010) and in hiding in the infection of EBV.This shows that Epstein-Barr virus miRNA can act on the one hand the target gene of virus itself, promote the infection of virus and hide, also can act on host's target gene on the other hand, promote virus to escape the immunoreation of host cell, and suppress the apoptosis of host cell.
Yet; The effect of relevant Epstein-Barr virus miR-BART3 and Study on Mechanism are but seldom; The miRNA (miR-BART1-5p, miR-BART16 and miR-BART17-5p) of 3 kinds of Epstein-Barr virus codings of Lo etc. (PNAS 104:16164-9,2007) report can reduce the LMP1 expression of gene of Epstein-Barr virus.When LMP1 received viral miRNA regulation and control, its downstream signal approach can be suppressed, and NF-KB expresses reduction, and apoptosis is suppressed, and made the cell of ebv infection easy in tumor development (Cell Mol Immunol 4:185-96,2007).Other has report EBV-miR-BART1 to combine with BBLF4 and LMP2A mRNA 3 ' end, thus reach the viral autogene expression of adjusting purpose (PNAS, 1993,90:378-382).Importantly, up to now, about any report is not seen in the effect of Epstein-Barr virus miR-BART3 and the especially short nasopharyngeal carcinoma Invasion and Metastasis of other Epstein-Barr virus miRNA promotion nasopharyngeal carcinoma incidence and development yet.
Nano-particle has advantages such as small-size effect, skin effect; Through strengthening infiltration and stick effect (EPR) target tumor zone effectively; The Recent study nano medicament carrying system is applied to oncotherapy becomes focus (Biomacromolecules.11,3531-3538,2010).Nano-particle can wrap up, concentrate, protects nucleotide, makes it avoid nuclease degradation; Through surface-functionalized, can connect the special target molecule; The body-internal-circulation time obviously is longer than the common size granule, and the nano-particle below the 100nm can be escaped engulfing of reticuloendothelial system, thereby prolongs administration time, improves administering effect; Suitable nano gene medicine can either be brought into play the advantage of the external high efficiency transfection of cationic polymer; Also can effectively avoid the removing of reticuloendothelial system in the experimentation in the body; Improve therapeutic effect, therefore nanotechnology is applied to gene therapy has the good clinical application prospect.Particle diameter is that the gold grain (AuNP) of 1nm～150nm is an inert substance, and nontoxic, method for preparing is simple; Cost is lower; Have special optical property and excellent biological compatibility and surface and be easy to advantages such as functionalization, can combine, be widely used in biomedical sector (Adv.Drug Deliv.Rev.60 such as immune labeled, biochip, bio-sensing and delivery system with drug molecule, biomacromolecule etc.; 1307-1315,2008).Be carrier with the gold nano grain in recent years, the base group modification of suitable functionalization is carried out on the surface, and further again load AMO, siRNA etc. carry out gene therapy and obtained many gratifying achievements.Research team of Northwestern Univ USA; Application 1 3nm left and right sides gold grain is stablized multiply sulfhydrylation oligonucleotide, makes it advance cell ability and strengthens greatly, and the nucleic acid (mRNAs) that can be tied to the target courier makes its down-regulated expression; And has nuclease-resistant character; Transfection efficiency is higher than not through the oligonucleotide of modifying and commodity with transfection lipid carrier Lipofectamine2000 (Science.312,27-30,2006); The gold nano grain that Klibavov group will have low-molecular-weight PEI (2KDa) advances MK cells COS-7 as carrier transfection DNA; Not only increased the effective molecular weight of PEI but also reduced its cytotoxicity; The more single PEI of transfection efficiency has increased by 12 times (Proc.Natl.Acad.Sci.USA.100 (16): 9138-9143,2003).
Summary of the invention
The object of the present invention is to provide a kind of medicinal usage of Epstein-Barr virus miR-BART3 antisense oligonucleotide; The medicine that embodies this purposes can combine with Epstein-Barr virus miR-BART3 effectively; The expression of blocking-up miR-BART3 and to the regulation and control facilitation of nasopharyngeal carcinoma Invasion and Metastasis, thus reach the purpose of anti-nasopharyngeal carcinoma Invasion and Metastasis and treatment nasopharyngeal carcinoma.
The medicinal usage of above-mentioned Epstein-Barr virus miR-BART3 antisense oligonucleotide specifically is; The application of Epstein-Barr virus miR-BART3 antisense oligonucleotide in the medicine of the anti-nasopharyngeal carcinoma Invasion and Metastasis of preparation, the sequence of wherein said antisense oligonucleotide is ACACCUGGUGACUAGUGGUGCG (SEQ ID NO:1).
Antisense oligonucleotide of the present invention adopts this area conventional method synthetic, as, adopt the nucleic acid synthesizer synthetic earlier, again through simple strand chemical modification (as, 2 '-methoxy is modified, and becomes the enhancement mode oligonucleotide) and the HPLC purification make.The method that the inventor recommends is made up of following steps:
1. the design of antisense oligonucleotide probe
(1.1) according to the Epstein-Barr virus miR-BART3 sequence among the public sanger mirbase data base in the world, carry out the antisense design, obtain Antisensedigonucleotsequence sequence; Wherein the basic principle of probe design is, 1) hairpin structure of probe interior is no more than 2; 2) through BLAST relatively with the similarity of other sequence less than 20%; 3) relatively be no more than 3 bases continuously through BLAST with the repetition of other gene order;
(1.2) adopt 21-23 nt 2`-methoxy to modify, obtain sequence shown in the SEQ ID NO:1;
2. antisense oligonucleotide probe synthesizes and purification
(2.1) it is synthetic automatically the sequence shown in the SEQ ID NO:1 to be imported 3900 synthesizers, obtains containing the synthetic post of the antisense oligonucleotide of sequence shown in the SEQ ID NO:1;
(2.2) synthetic post is carried out eluting and collects eluent, then, freezing, dry, deammoniation water is dissolved in 9: 1 the first phthalein amine and TBE mixed solution;
(2.3) be splined on HPLC and carry out purification;
(2.4) obtain the antisense oligonucleotide that sequence is SEQ ID NO:1 after alcohol precipitation, washing, vacuum are drained ,-20 ℃ of preservations are subsequent use.
The present invention utilizes transfer and invasion and attack test (Transwell experiment and the experiment of Boyden cell) analysis to find in nasopharyngeal carcinoma cell, to be invasion and attack and the transfer that the Epstein-Barr virus miR-BART3 that highly expresses can obviously promote nasopharyngeal carcinoma cell.After the miR-BART3 transfection of Epstein-Barr virus coding advanced human nasopharyngeal epithelioma 1 CNE1; Compare with the CNE1 cell strain that does not have transfection Epstein-Barr virus miR-BART3; The quantity of cell-penetrating filter membrane and matrix membrane significantly increases, and shows the migration and the invasion and attack of this miRNA regulation and control promotion nasopharyngeal carcinoma cell.
The inventor with Epstein-Barr virus miR-BART3 antisense oligonucleotide effect nasopharyngeal carcinoma cell after; Epstein-Barr virus miR-BART3 expression generation significant difference changes (Welch/F=104.400; P=0.000; 24h and 48h disturb and suppress efficient and all can reach more than 80% (show that its Antisense Suppression effect can keep at least two days); Show that the quantity of passing filter membrane and matrix membrane obviously reduces through the obviously reduction of transfer invasive ability appearance of the nasopharyngeal carcinoma cell of Epstein-Barr virus miR-BART3 antisense oligonucleotide effect.
The medicine of treatment nasopharyngeal carcinoma of the present invention by Epstein-Barr virus miR-BART3 antisense oligonucleotide and pharmaceutically the acceptable excipient form.
In order to improve drug effect, preferably earlier Epstein-Barr virus miR-BART3 antisense oligonucleotide is adsorbed on the nanosphere, and then the adding appropriate excipients is processed needed dosage form.
The particle diameter of nanosphere of the present invention is 30nm～50nm, and this nanosphere is that PEI, antisense oligonucleotide and the poly glycol monomethyl ether of 2Kda and the copolymer of branched chain type PEI are formed by the nanometer gold that contains sulfydryl, molecular weight; Described nanosphere can be prepared by following method:
Nanometer gold and the quality that (a) will contain sulfydryl is that the molecular weight that contains 10 times of the nanometer gold of sulfydryl is that the PEI of 2Kda adds in the 1mM NaCl solution, room temperature reaction 30 minutes down, and centrifugal purification separates and obtains PEI parcel nanometer gold;
(b) be that the sequence that contains 80 times of the nanometer gold of sulfydryl is in the antisense oligonucleotide adding 1mM NaCl solution of SEQ ID NO:1 with the PEI parcel nanometer gold of step (a) preparation and quality; Room temperature reacted 30 minutes down, and the centrifugal purification separation obtains load antisense oligonucleotide nano gold;
(c) be that poly glycol monomethyl ether and the copolymer of branched chain type PEI that contains 6 times of the nanometer gold of sulfydryl adds in the 1mM NaCl solution with load antisense oligonucleotide nano gold, the quality of step (b) preparation; Room temperature reacted 30 minutes down; The centrifugal purification separation obtains nanosphere wherein; The molecular weight of poly glycol monomethyl ether is 2Kda, and the molecular weight of branched chain type PEI is 25Kda, and the ratio of poly glycol monomethyl ether and the amount of substance of branched chain type PEI is 1: 1.5.
In the method for preparing of above-mentioned nanosphere, but the report of the method for preparing reference literature of described copolymer (as: Macromolecules, 35,6867-6874,2002).
In the method for preparing of above-mentioned nanosphere, the described particle diameter that contains the nanometer gold of sulfydryl is 15～20nm.Wherein, the described nanometer gold that contains sulfydryl can be according to this area method preparation commonly used, the report (as: ACS Nano, 4 (9): 5505-5511,2010) that concrete steps can reference literature.
The miRNA of antisense oligonucleotide of the present invention Epstein-Barr virus coding capable of blocking duplicates, survives and expresses; Its base sequence combines with the sequence of reverse complemental; Have the specificity higher than antibody; Make the nasopharyngeal carcinoma Invasion and Metastasis receive effective inhibition, and the miRNA non-immunogenicity, help preventing and treating better the recurrence and the transfer of nasopharyngeal carcinoma.Further; The present invention is prepared into the nano gene medicine with described antisense oligonucleotide, avoids nuclease degradation with the protection antisense oligonucleotide, prolongs action time; With liposome higher transfection efficiency is arranged than commodity, help further clinical practice development and application.
Description of drawings
Fig. 1 is the rectangular histogram of Epstein-Barr virus miR-BART3 antisense oligonucleotide Transwell shift experiment of the present invention; Control is not for adding the human nasopharyngeal epithelioma 1 Transwell shift experiment result of antisense oligonucleotide among the figure, and BART3-AMO is the human nasopharyngeal epithelioma 1 Transwell shift experiment result after the effect of antisense.
Fig. 2 is an Epstein-Barr virus miR-BART3 antisense oligonucleotide Boyden cell invasion and attack experiment rectangular histogram of the present invention; Control is not for adding the human nasopharyngeal epithelioma 1 Boyden cell invasion and attack experimental result of antisense oligonucleotide among the figure, and BART3-AMO is the human nasopharyngeal epithelioma 1 Boyden cell invasion and attack experimental result after the effect of antisense.
The specific embodiment
Embodiment 1
1, contains the preparation of the human nasopharyngeal epithelioma 1 CNE1 of Epstein-Barr virus miR-BART3;
Cell:
CNE1 cell strain: available from Hunan Xiangya Medical College, Zhongnan Univ central laboratory.
Cross the CNE1 cell preparation of expressing miR-BART3: chemosynthesis Epstein-Barr virus miR-BART3 precursor molecule sequence (282bp); Be connected among the slow virus carrier pMAGic 4.0 that contains the GFP expression; Through pNL-EGFP/CMV/WPREDU3 vector plasmid, pCD/NL-BH*DDD packaging plasmid and pLTR-G plasmid; Packing in the 293T cell, generation can be expressed the slow virus carrier pMAGic-EB virus miR-BART3 of Epstein-Barr virus miR-BART7.With this slow virus carrier transfection human nasopharyngeal epithelioma 1 CNE1, through the streaming sub-sieve, quantitative PCR confirms, obtains the CNE1 (containing GFP expresses) that Epstein-Barr virus miR-BART3 stablizes high expressed.Concrete steps can reference literature (Nanfang Medical Univ's journal 2011; 31 (3): 419).
Oligonucleotide: the sequence of Epstein-Barr virus miR-BART3 antisense oligonucleotide is SEQ ID NO:1, entrusts Shanghai JiMa pharmacy Technology Co., Ltd synthetic.
In addition, for the miR-BART3 of Epstein-Barr virus coding and the biological activity test of antisense oligonucleotide thereof, all use commercialization liposome Lipofectamine2000 to carry out transfection as carrier.
Epstein-Barr virus miR-BART3 antisense oligonucleotide suppresses the active assay method of Epstein-Barr virus miR-BART3:
(1) cell transfecting: get monolayer and cross the human nasopharyngeal epithelioma 1 of expressing miR-BART3, be inoculated in 6 orifice plates not contain antibiotic 10% calf serum complete medium (PBR1640 or DMEM) cultivation, 37 ℃, 5% CO
2Incubated overnight, next day, every hole is with anteserum-less substrate dilution lipofectamine 2000; Incubated at room 5min is simultaneously with anteserum-less substrate dilution Epstein-Barr virus miR-BART3 antisense oligonucleotide, the lipofectamine 2000 of mixed diluting and the Epstein-Barr virus miR-BART3 antisense oligonucleotide of dilution; Room temperature held 20min, 6 orifice plate cells wash 2 times after removing the training base; After adding the 2mL anteserum-less substrate, mixed liquor is added in every hole mixing gently, 37 ℃; After 5% CO2 incubator is hatched 6h, change and contain the full culture medium of 10% calf serum, use the transfection level of fluorescence quantitative PCR detection different time.
(2) fluorescence quantitative PCR detection transfection level: the vessel of the RNA that is useful on preparation all through going RNase to handle, required liquid is all prepared with the DEPC water of deactivation.The extracting of cell total rna is carried out according to TRIzol reagent description.The human nasopharyngeal epithelioma 1 of trophophase of taking the logarithm is cultured to cell density to be measured, washes 2 times with the PBS of pre-cooling, adds 1mL TRIzol, leave standstill 5min on ice after lysate be transferred to 1.5mL EP pipe; Add chloroform 0.2mL, shaken 15sec, room temperature is placed the centrifugal 15min of 12000rpm 4oC after 5 minutes, sucking-off upper strata water; Lower floor is transferred to another 1.5ml EP pipe, adds isopropyl alcohol by equal proportion, and room temperature leaves standstill 5min behind the mixing; Centrifugal 30min, 75% washing with alcohol deposition, centrifugal 10 minutes; Lower floor is natural drying 5-10min in super-clean bench, treats ethanol volatilization back with an amount of DEPC water dissolution, and-80 ℃ of preservations are subsequent use.A260 and A280 are measured in RNA BIAO and BEN dilution back, calculate RNA concentration and purity, and electrophoresis detection RNA has or not degraded in 1% agarose gel.Detect intact RNA and be used to carry out reverse transcription reaction, carry out the synthetic of cDNA according to the TIANScript cDNA first chain synthetic agent box.Use the transfection level of fluorescence quantitative PCR detection different time.
2, the experiment of Epstein-Barr virus miR-BART3 antisense oligonucleotide anti-nasopharyngeal cancer cell invasion and attack;
Prepare artificial basement membrane with matrigel chamber on Transwell, respectively organizing cell before and after the transfection, to use anteserum-less substrate to be diluted to density be 1 * 10
6The cell suspension of/ml, 100 μ L cell suspension add Transwell and go up the chamber, and following chamber adds 600 μ L conditioned mediums, 37 ℃ 5%, CO
2After incubator is hatched 36h, take out the Transwell cell, inhale and abandon liquid, clean Matrigel with cotton swab, formaldehyde fixed 30min after the PBS rinsing, brazilwood extract dyeing.Mirror is counting (4 visuals field of average counter) down, and more than experiment is independent repeats 3 times.The result is as shown in Figure 1.Fig. 1 shows; Compare with the human nasopharyngeal epithelioma 1 that has Epstein-Barr virus-miR-BART1-5p; Cell after the effect of antisense of Epstein-Barr virus miR-BART3; Cell-penetrating filter membrane quantity reduces, and has significant difference (P＜0.0000), explains that the antisense oligonucleotide of Epstein-Barr virus miR-BART3 has suppressed the migration of nasopharyngeal carcinoma cell.
3, Epstein-Barr virus miR-BART3 antisense oligonucleotide suppresses the experiment that nasopharyngeal carcinoma cell shifts.
Identical with Transwell invasion and attack experiment, just Transwell goes up the chamber and need not use artificial basement membrane covering, experiment independent repetition 3 times.The result is as shown in Figure 2.Fig. 2 shows; Compare with the human nasopharyngeal epithelioma 1 that has Epstein-Barr virus miR-BART3; Cell after the effect of antisense of Epstein-Barr virus miR-BART3; Cell-penetrating matrix membrane quantity reduces, and has significant difference (P＜0.0000), explains that the antisense oligonucleotide of Epstein-Barr virus miR-BART3 has suppressed the invasion and attack of nasopharyngeal carcinoma cell.
Can know that from Fig. 1 and Fig. 2 Epstein-Barr virus miR-BART3 antisense oligonucleotide has suppressed the migration and the invasion and attack of nasopharyngeal carcinoma cell, have treatment nasopharyngeal carcinoma effect.
Embodiment 2
1. the preparation of nanosphere
1.1 preparation PEI parcel nanometer gold
The nanometer gold adding concentration that will contain sulfydryl is the NaCl solution of 1mM, and adjustment nanometer gold concentration is 0.1mg/mL; In reactant liquor, add PEI (PEI, Mw=2k) to PEI concentration be 1.0mg/mL, normal-temperature reaction 30 minutes, with 157500xg centrifugal 10 minutes, repeat 2 times, prepare PEI parcel gold nano; PEI is wrapped up nanometer gold be resuspended in the NaCl solution that concentration is 10mM, obtain 0.1mg/mL PEI parcel nanometer gold NaCl solution, for use;
The nanometer gold that wherein contains sulfydryl can prepare according to following method:
Get 100mL aqueous solution of chloraurate (0.01%); Be heated to and boil, stir down accurately adding 1% trisodium citrate aqueous solution 2mL, flavous aqueous solution of chloraurate became orange red in 5 minutes; Continued to boil 15 minutes; After the cooling, remove macroparticle, return to original volume with distilled water with the filter membrane of 220nm; Getting freshly prepd aurosol solution, to use the NaOH solution adjustment pH value of 1N be 11, and adding 11-sulfydryl hendecanoic acid is 0.1mg/mL to final concentration, and stirring at normal temperature is spent the night, with centrifugal rotational speed 157500xg centrifugal 10 minutes, repeat 2 times, and obtain containing the sulfydryl nanometer gold.Detecting the nanometer gold particle diameter that contains sulfydryl through TEM is 15～20nm.
1.2. the nanometer gold of preparation load antisense oligonucleotide
Get 0.1mg/mL PEI parcel nanometer gold NaCl solution 5.5mL; Adding sequence is the Epstein-Barr virus miR-BART3 antisense oligonucleotide 4.0mg of SEQ ID NO:1, and room temperature stirred 30 minutes down, with 157500xg centrifugal 10 minutes; Repeat 2 times, obtain load antisense oligonucleotide gold nano.Load antisense oligonucleotide nano gold is resuspended in the NaCl solution that concentration is 10mM, obtains 0.1mg/mL load antisense oligonucleotide nano gold NaCl solution, for use;
1.3. preparation nanosphere
Get 0.1mg/mL load antisense oligonucleotide nano gold NaCl solution 10mL; Adding molecular weight is the poly glycol monomethyl ether 3.3mg of 2Kda and the branched chain type PEI 62.6mg that molecular weight is 25Kda, normal-temperature reaction 30 minutes, with 157500xg centrifugal 10 minutes; Repeat 2 times, obtain nanosphere.Nanosphere is added the NaCl solution that concentration is 10mM, and sealing is preserved.
2. nanosphere Performance Detection
Use the demonstration absworption peak of ultraviolet light spectrophotometric determination nanosphere at 519nm and 260nm place.Wherein, 519nm place absworption peak is the characteristic absorption peak of nanometer gold; 260nm place absworption peak is the nucleic acid characteristic absorption peak.
Utilize transmission electron microscope (TEM) to observe the carrying medicament nanosphere, particle diameter is 30～50nm.
3. Epstein-Barr virus in the inhibition nasopharyngeal carcinoma cell-miR-BART3 effect
Expression and effective acting time that this antisense oligonucleotide nano ball of the antisense oligonucleotide of sequence SEQ ID NO:1 and load suppresses Epstein-Barr virus-miR-BART3 among the nasopharyngeal carcinoma cell CNE1
3.1 nanosphere suppresses Epstein-Barr virus miR-BART3 experiment in the nasopharyngeal carcinoma cell:
Get monolayer and cross the nasopharyngeal carcinoma CNE1 cell strain of expressing miR-BART3, be inoculated in 6 orifice plates, 37 ℃ not contain antibiotic 10% calf serum PBR1640 culture medium culturing; 5% CO2 incubated overnight, next day is after 6 orifice plate cells are removed the training base; Wash 2 times, every hole adds 2mL and is loaded with antisense oligonucleotide nano ball (containing antisense oligonucleotide 5nmol), mixing gently with the anteserum-less substrate dilution; 37 ℃, after 5% CO2 incubator is hatched 6h, change and contain the full culture medium of 10% calf serum.Simultaneously, as control samples, the cell of untransfected Epstein-Barr virus miR-BART3 antisense oligonucleotide compares experiment as blank with Lipofectamine2000 transfection Epstein-Barr virus miR-BART3 antisense oligonucleotide.In whole experiment, collect transfection respectively before, the cell after the transfection when 24h and 48h.
3.2. the application fluorescence quantitative PCR detection is to inhibition effect and the effective acting time of Epstein-Barr virus miR-BART3
3.2.1 the cell to collecting carries out total RNA extracting respectively
The human nasopharyngeal epithelioma 1 of trophophase of taking the logarithm is cultured to cell density to be measured, washes 2 times with the PBS of pre-cooling, adds 1mLTRIzol, leave standstill 5min on ice after lysate be transferred to 1.5mL EP pipe; Add chloroform 0.2mL, shaken 15sec, room temperature is placed 4 ℃ of following centrifugal 15min of 12000rpm after 5 minutes, sucking-off upper strata water; Lower floor is transferred to another 1.5ml EP pipe, adds the equal proportion isopropyl alcohol, and room temperature leaves standstill 5min behind the mixing; Centrifugal 30min, 75% washing with alcohol deposition, centrifugal 10 minutes; Lower floor is natural drying 5～10min in super-clean bench, treats that ethanol volatilization back obtains total extracting RNA with the DEPC water dissolution, and-80 ℃ of preservations are subsequent use.A260 and A280 are measured in total extracting RNA BIAO and BEN dilution back, calculate RNA concentration and purity, and the total extracting RNA of electrophoresis detection has or not degraded in 1% agarose gel.
3.2.2. the expression of fluorescence quantitative PCR detection Epstein-Barr virus miR-BART3
3.2.2.1. according to TaqMan MiRNA Reverse Transcription Kit description, total extracting RNA BIAO and BEN is carried out reverse transcription reaction, synthetic cDNA
(a) in the EP of DEPC water treatment pipe, add 10 * RT buffer, 1.5 μ l, dNTP 0.15 μ l, RNaseInhibitor 0.19 μ l, RT enzyme 1 μ l earlier; Add 3 μ l specificity RT primer, the total extracting RNA BIAO and BEN of 5 μ l, mixing gently again.
(b) place 5min on ice after, place on the T1 Thermocycler PCR appearance, reaction condition be set be: 16 ℃ of 30min, 42 ℃ of 30min, 85 ℃ of 5min, 4 ℃ of terminations obtain reverse transcription cDNA.
3.2.2.2. quantitative fluorescent PCR reaction
According to TaqMan MiRNA Assay description, carry out the quantitative fluorescent PCR reaction: in 8 pipes, add Nuclease freewater 3.835 μ l, 2 * Master mix, 5 μ l, TaqMan MiRNA Assay (20 *) 0.5 μ l, reverse transcription cDNA0.665 μ l; Reaction condition is set is: 95 ℃ of preparatory degeneration 10min; Be 95 ℃ of 15s, 60 ℃ of 60s then, 45 circulations are reacted on fluorescent quantitation Mx3000PCR appearance.Experiment all repeats 3 times.The result shows with the Ct value.Adopt the relatively Epstein-Barr virus miR-BART1-5 expression of collecting cell of relative quantification method.
Mensuration result is as shown in table 1.Visible by table 1; Compare with blank; After the Lipofectamine2000 transfection, the antisense oligonucleotide of sequence SEQ ID NO:1 can effectively suppress the miR-BART3 expression at 24 hours, 48 hours, and corresponding Nano medication can reach better inhibition effect.With commodity with liposome Lipofectamine2000 transfection comparison, Nano medication has higher inhibition effect, prolongs effective acting time, action time can be more than 48 hours.
The inhibition effect of table 1 nanosphere
Embodiment 3
Get the nanosphere of 40mg embodiment 1 preparation and the aseptic NaCl aqueous solution of 10mM of 500 μ l, add an amount of antiseptic and stabilizing agent, be formulated as injection.
Embodiment 4
Get in the nanosphere of 40mg embodiment 1 preparation and the aseptic NaCl aqueous solution of 10mM that ethylparaben 0.0135g is dissolved in 500 μ l, filtration under diminished pressure obtains spray.
Claims (2)
1.EB the application of viral miR-BART3 antisense oligonucleotide in the medicine of preparation treatment nasopharyngeal carcinoma, the sequence of wherein said antisense oligonucleotide is ACACCUGGUGACUAGUGGUGCG (SEQ ID NO:1).
2. the described application of claim 1 is characterized in that, described medicine is said antisense oligonucleotide to be loaded to process nanosphere on the nanometer gold earlier, adds pharmaceutically the acceptable adjuvant again and processes; Wherein, the particle diameter of described nanosphere is 30nm～50nm, and this nanosphere is that PEI, antisense oligonucleotide and the poly glycol monomethyl ether of 2Kda and the copolymer of branched chain type PEI are formed by the nanometer gold that contains sulfydryl, molecular weight; Described nanosphere can be prepared by following method:
Nanometer gold and the quality that (a) will contain sulfydryl is that the molecular weight that contains 10 times of the nanometer gold of sulfydryl is that the PEI of 2Kda adds in the 1mM NaCl solution, room temperature reaction 30 minutes down, and centrifugal purification separates and obtains PEI parcel nanometer gold;
(b) be that the sequence that contains 80 times of the nanometer gold of sulfydryl is in the antisense oligonucleotide adding 1mM NaCl solution of SEQ ID NO:1 with the PEI parcel nanometer gold of step (a) preparation and quality; Room temperature reacted 30 minutes down, and the centrifugal purification separation obtains load antisense oligonucleotide nano gold;
(c) be that poly glycol monomethyl ether and the copolymer of branched chain type PEI that contains 6 times of the nanometer gold of sulfydryl adds in the 1mM NaCl solution with load antisense oligonucleotide nano gold, the quality of step (b) preparation; Room temperature reacted 30 minutes down, and the centrifugal purification separation obtains nanosphere; Wherein, the molecular weight of poly glycol monomethyl ether is 2Kda, and the molecular weight of branched chain type PEI is 25Kda, and the ratio of poly glycol monomethyl ether and the amount of substance of branched chain type PEI is 1: 1.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110122249 CN102188719B (en) | 2011-05-12 | 2011-05-12 | Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110122249 CN102188719B (en) | 2011-05-12 | 2011-05-12 | Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102188719A CN102188719A (en) | 2011-09-21 |
| CN102188719B true CN102188719B (en) | 2012-12-19 |
Family
ID=44598148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110122249 Expired - Fee Related CN102188719B (en) | 2011-05-12 | 2011-05-12 | Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102188719B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109321655B (en) * | 2018-05-17 | 2022-07-05 | 福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心） | NKIRAS2 gene regulatory region sequence, regulatory sequence and application thereof in nasopharyngeal carcinoma |
| CN110079604A (en) * | 2019-06-14 | 2019-08-02 | 福建省肿瘤医院（福建省肿瘤研究所、福建省癌症防治中心） | A kind of marker and its application for detecting nasopharyngeal carcinoma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101861399A (en) * | 2007-08-22 | 2010-10-13 | 申诺米克斯公司 | Methods of using miRNA for detection of in vivo cell death |
-
2011
- 2011-05-12 CN CN 201110122249 patent/CN102188719B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101861399A (en) * | 2007-08-22 | 2010-10-13 | 申诺米克斯公司 | Methods of using miRNA for detection of in vivo cell death |
Non-Patent Citations (2)
| Title |
|---|
| 李欣等.EB病毒潜伏膜蛋白LMP1编码基因沉默对NF-κB表达的影响.《现代生物医学进展》.2009,第9卷(第6期),1040-1043. * |
| 涂露霞等.慢病毒介导的siRNA靶向干扰EIF4G1鼻咽癌稳定细胞株的建立.《南方医科大学学报(J South Med Univ)》.2009,第29卷(第5期),844-847,851. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102188719A (en) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160375050A1 (en) | Methods and compositions involving chitosan nanoparticles | |
| Ma et al. | Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo | |
| CN108175759A (en) | A kind of antineoplastic target drug delivery system and preparation method and application | |
| WO2023051822A1 (en) | Targeting oligonucleotide for treating diseases associated with pcsk9 | |
| CN108175861A (en) | A kind of delivery system of antitumor small nucleic acids drug and its application | |
| CN102188719B (en) | Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma | |
| CN103849652B (en) | A kind of nano-carrier complex for microRNA targeted delivery and preparation method thereof and application | |
| CN102908315B (en) | Chitosan (CS) nanoparticle delivery system of small molecular interfering ribonucleic acid and preparation method thereof | |
| CN110897998B (en) | Genetic engineering polypeptide nano hydrogel simultaneously loaded with hydrophobic drug and hydrophilic drug and preparation method thereof | |
| CA3063429A1 (en) | Cationic liquid crystalline nanoparticles | |
| CN113170792A (en) | Preparation of nano prodigiosin preparation and application of nano prodigiosin preparation in prevention and treatment of vegetable economic crop virus diseases | |
| CN102218147A (en) | Use of epstein-barr virus miR-BART7 antisense oligonucleotide in preparing drugs for treating nasopharyngeal carcinoma | |
| CN102218148A (en) | Use of epstein-barr virus miR-BART1-5p antisense oligonucleotide in preparing drugs for treating nasopharyngeal carcinoma | |
| CN114869858B (en) | Nucleic acid-chemotherapeutic drug composite nano-particles coated by homologous cancer cell membrane | |
| CN113262307B (en) | Nano-composite carrier for transfection, nucleic acid nano-drug, preparation method and application thereof | |
| CN101229183B (en) | Ribonucleic acid retrogradation snippet compound and applications thereof | |
| WO2022206781A1 (en) | Rna delivery system for treating colitis | |
| WO2023138451A1 (en) | Sirna pharmaceutical composition for inhibiting her2 and her3 | |
| CN115137737A (en) | RNA delivery system for treating pulmonary fibrosis | |
| CN108939090B (en) | Liposome, preparation method and application | |
| CN115463148A (en) | Small interfering nucleic acid pharmaceutical composition and preparation for treating skin tumor | |
| CN117731797A (en) | Stimulus-responsive lipopeptide delivery system, and preparation method and application thereof | |
| CN105779452A (en) | Oligonucleotide capable of inhibiting tumor growth and application of oligonucleotide | |
| CN100430412C (en) | Nucleic acid molecule RTN4BSR6 and application for preparation of anti-cancer drugs | |
| CN115141845A (en) | RNA plasmid delivery system for treating lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121219 Termination date: 20170512 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |